EZZ Life Science Holdings Ltd
ASX:EZZ
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.46
4.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
EZZ Life Science Holdings Ltd
Cash & Cash Equivalents
EZZ Life Science Holdings Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Cash & Cash Equivalents
AU$19m
|
CAGR 3-Years
29%
|
CAGR 5-Years
115%
|
CAGR 10-Years
N/A
|
|
|
Anteotech Ltd
ASX:ADO
|
Cash & Cash Equivalents
AU$5m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Cash & Cash Equivalents
AU$6.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Cash & Cash Equivalents
AU$11.2m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Cash & Cash Equivalents
AU$703k
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
3%
|
|
|
Genetic Signatures Ltd
ASX:GSS
|
Cash & Cash Equivalents
AU$36.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
EZZ Life Science Holdings Ltd
Glance View
EZZ Life Science Holdings Ltd. engages in wholesale distributor of skin care products under the EAORON brand to pharmacies, supermarkets and specialist retailers. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-03-03. The firm is wholesale distributor of EAORON skin care products for the Australian and New Zealand markets. The company develops, manufactures and distributes genetic technology enabled consumer health products under its own brand, EZZ. The EAORON brand comprises of five product lines, including Hyaluronic Series, Facial Mask Series, Crystal White Series, Specific Care Series and Anti-Sugar Series. The EZZ products cover market segments, including vitamin and dietary supplements, sports nutrition, wright management and wellbeing, herbal/ traditional and pediatric consumer health products.
See Also
What is EZZ Life Science Holdings Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
19m
AUD
Based on the financial report for Jun 30, 2024, EZZ Life Science Holdings Ltd's Cash & Cash Equivalents amounts to 19m AUD.
What is EZZ Life Science Holdings Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
115%
Over the last year, the Cash & Cash Equivalents growth was 38%. The average annual Cash & Cash Equivalents growth rates for EZZ Life Science Holdings Ltd have been 29% over the past three years , 115% over the past five years .
You don't have any saved screeners yet
